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In Brief
Silberberg et al. studied the properties of 91 enhancers with activity in the embryonic subpallium (basal ganglia) using transgenic assays, transcription factor ChIP-seq, and fate mapping using ten novel enhancer lines.
INTRODUCTION
The subpallium is the telencephalic region that contains the striatum, pallidum, diagonal zone, preoptic area, and large parts of the septum and amygdala. Each of these domains is generated by distinct progenitor zones known as the caudal, lateral, and medial ganglionic eminences (CGE, LGE, and MGE), diagonal zone (DG), preoptic area (POA), and septum (Se) (Flames et al., 2007; Rubenstein and Campbell, 2013; Puelles et al., 2013 Puelles et al., , 2015 . In addition to generating GABAergic and cholinergic projection neurons that migrate locally into nuclei, the CGE, DG, LGE, MGE, and POA generate interneurons that tangentially migrate and integrate within the subpallium and pallium (Batista-Brito and Fishell, 2013) .
Gene expression, fate-map studies, and mouse genetic functional analyses are defining a map of the molecular regulation of developmental origins and differentiation of subpallial neurons and glia (Rubenstein and Campbell, 2013; Batista-Brito and Fishell, 2013; Puelles et al., 2015) . However, a major gap in our understanding of subpallial development lies in the genomic mechanisms that regulate gene expression in specific developmental and adult regions. Recently, we identified hundreds of candidate enhancer elements that have region-specific activity in the developing telencephalon Nord et al., 2013; Pattabiraman et al., 2014) . Approximately 90 had activity in the embryonic day 11.5 (E11.5) subpallium and not in the pallium and herein) . However, the mechanisms that regulate these enhancers have not been investigated nor have the fates of the cells that have E11.5 enhancer activity been defined.
Here, we focused on ten subpallial enhancers with varying regional and laminar activities in the E11.5 subpallium by generating stable mouse transgenic lines that express CreER (tamoxifen-regulated Cre recombinase) and GFP. Using these ten enhancer lines, we derived CreER-mediated fate maps and followed enhancer activity over development. We elucidated the lineages generated by specific progenitor zones and identified enhancers with activity in specific cells types (immature and mature).
Next, we investigated transcriptional mechanisms that control enhancer activity in specific subpallial regions and in distinct developmental layers (ventricular, subventricular, and mantle zones [VZ, SVZ, and MZ] ). By combining transcription factor (TF) chromatin immunoprecipitation and DNA sequencing (chromatin immunoprecipitation sequencing [ChIP-seq] ) with machine learning, we identified TFs that are associated with region-and layer-specific enhancer activities. We tested some of the hypotheses generated by those analyses with specific genetic tests on one enhancer (799) and demonstrated that Dlx1&2 and Lhx6 are critical regulators of its activity. Thus, these subpallial enhancer transgenic lines are data and tool resources to investigate new aspects of transcriptional regulation of GABAergic cell fate. Furthermore, these short enhancer elements have utility for multiple other types of experiments, including their use to drive cell-type-specific expression following their transduction in vivo or into stem cells.
RESULTS
Toward identifying enhancers with activity that mark regional and laminar subdivisions and cell lineages in the E11.5 subpallium, we surveyed a large collection of human and mouse enhancers active in the developing telencephalon defined using a mouse transgenic assay ; http://enhancer.lbl. gov/). We identified $90 enhancers that had subpallial activity in the E11.5 subpallium; many had little or no activity in the E11.5 pallium (Table S1 ). Of these, we concentrated on ten human enhancers that had the following properties: (1) they had regional activity within subpallial subdivisions and/or subpallial layers ( Figure 1 ; Table S1 ) and (2) most enhancers mapped to a genomic region near a gene with a known role in regulating subpallial development (Table S3 ). For instance, 599 (Meis2) and 841 (Vax1) were predominately active in the LGE (and septum in the case of 841); 692 (Sox6), 799 (Nxph1), 1056 (Sall3), and 1538 (Nkx2-1) were active in the MGE and POA; and 953 (Sp9) and 1060 (Nr2f1; COUPTF1) were active in the CGE. Enhancers were also selected based on their cell layer specificity: 841, 1056, and 1538 for their VZ activity and 192 (Sox2 OT), 204, 599, 799, 953 , and 1060 for their MZ activity (Figure 1 ; Tables S1 and S2).
Enhancer Activity of Subpallial Enhancer CreER
T2 -IRES-GFP Alleles at E11.5
To test the hypothesis that these enhancers were active in domains that generate distinct subpallial subdivisions and subpallium-derived cell types, we produced stable transgenic mouse lines using ten different human enhancers. Each enhancer was cloned into a construct encoding the Hsp68 minimal promoter, a tamoxifen inducible Cre sequence (CreERT2), and GFP (Pattabiraman et al., 2014) . GFP expression was used to track ongoing enhancer activity, while the CreERT2 was used for fate mapping (Hayashi and McMahon, 2002; Feil et al., 1997) . We generated one to three founders for each of the lines; when we had multiple founders, their expression patterns were largely reproducible (Table S3) ; Tables S2 and S3) , although some enhancer lines had broader expression, particularly extending into parts or all of the LGE (192, 692, 799, 841, and 1056) .
Enhancer activity had subpallial regional specificity: enhancer 599 in the LGE, enhancers 953 and 1060 in the CGE, and enhancers 799, 1056, and 1538 in the MGE and POA, whereas enhancers 192, 204, 692 , and 841 were more broadly active within the subpallium, although each showed interesting distinctive features (Figures 1A 0 -1J 0 ; Table S2 ). Enhancer activity also had laminar specificity: 1056 and 1538 were restricted to the VZ; 192, 599, 953 , and 1060 to the MZ, and 204 and 799 to the SVZ and MZ. Enhancer 692 and 841 activity encompassed the VZ, SVZ, and MZ. We diagrammatically annotated the E11.5 regional and laminar expression domains onto a topologic representation of the rostral forebrain (Figures 1A 00 -1J 00 ).
Fate Maps Derived From E11.5 Activity of the Subpallial Enhancer Lines
To test the anatomical assignments shown in the schemata of Figures 1A 00 -1J 00 , we performed fate-map analyses. The fates of cells with E11.5 enhancer activity were determined by inducing CreERT2 nuclear translocation (E10.5 tamoxifen dose), which led to tdTomato expression (from an Ai14 allele) assessed at multiple ages (Data S1A-S1J; Table S3 ). Prenatal tamoxifen frequently led to fetal death; thus, we obtained fatemapping data at E17.5 for all enhancer lines (Figures 2A-2J , Data S1A-S1J; Table S4 ). We also obtained postnatal day 40 (P40) fate maps for a subset of enhancer lines that fate mapped to cortical interneurons (Figures 3, 4, and 5; Tables S3 and S7) .
At each age, we assessed ongoing activity of the enhancers by examining GFP expression (Data S1A-S1J; Tables S2, S3 , and S7). For instance, enhancer 799 maintained GFP expression at E17.5 and P40 in cortical interneurons (Figures 4E and 4F ; Data S1F), and 1056 maintained GFP expression in OLIG2 + cortical cells at P40 ( Figure S3 ).
We also assessed whether or not Cre-mediated recombination was dependent on giving tamoxifen. Only two lines induced tdTomato expression in the absence of tamoxifen: 192 and 799. 192 had this activity only in the medial pallium, whereas 799 had this activity in its entire telencephalic domain-we are uncertain why these lines have this property, but it may relate to high expression of the allele.
Fate mapping using E11.5 CreERT2-induced recombination generated tdTomato + cells that were regionally restricted within the subpallium, consistent with the E11.5 GFP expression (Figures 2 and 3; Data S1; Figures S1 and S2) . In several cases, cells tangentially migrated to the cortex (Figures 2, 4 , and 5; Data S1) and olfactory bulb (OB) (Figure 2 ; Figures S1A-S1J). Below we focus on their subpallial fates (Figures 2 and 3 ; Data S1; Figures S1 and S2; summarized in Table S4 ).
Consistent with their LGE expression (Figure 1 ), some enhancer lines generated cells that contributed to the E17.5 olfactory bulb (599, 1056, 799, 692, 841, 204, and 192 ) (Figures S1A-S1J), the striatum (dorsal and ventral parts [Str and VSt] ) and the accumbens nucleus (ACb) (599, 1056, 799, 692, 841, 204, and 192) (Figure 2 ; Figures S1A 0 -J 0 ). (599, 953, 1060, 799, 841, 692, 204, 192) Enhancers with activity in the septal anlage ( Figure 1 ) generated cells in the E17.5 septum (204, 599, 692, 799, 841, and 1538) . 599 contributed to the intermediate septum (ISe), whereas 204, 799, and 1538 contributed to the medial septum (MSe) and diagonal band (DB).
Enhancers with MGE activity generated pallidal and/or diagonal area (DG) nuclei (192, 204, 692, 799, 841, 1056, and 1538) , including the bed nucleus stria terminals (BST), external and internal globus pallidus (GPE and GPI), ventral pallidum (VPal), and DB (Figures 2D-2J ; Data S1; Figure S2 ). Likewise enhancers with POA activity generated components of the preoptic nuclei (204, 692, 841, and 1538) (Figures 2D and 2G-2I ; Data S1).
Finally, enhancers with either MGE or CGE activity generated components of the subpallial amygdala (192, 204, 599, 692, 799, 841, 953, 1056, 1060, and 1538; Figure 2 ; Data S1; Figures S1A 00 -S1J 00 ). Enhancers with CGE activity (599, 953, and 1060) contributed to the central nucleus (Ce). Enhancer 1060, which had particularly restricted E11.5 CGE activity, contributed scattered cells to parts of Ce (CeC and CeM), the anterior amygdala (AAD), the medial amygdala (MA, MeAD, MePD, and MePV), and anterior cortical amygdala (ACo) (Figures S1C 00 and S4). Enhancers with different domains of MGE activity differentially contributed to the amygdala nuclei. 1538 generated a cluster of cells in the amygdala area of the bed nucleus stria terminalis (BSTA) ( Figure S1D 00 ). 799 generated cells in the medial amygdala (MeAD and MePD). Although 799 was primarily active in the MGE, it may also have some LGE/CGE activity, as it fate maps to striatal patch-like domains rostrally and to the Ce caudally (Figures S1F 0 and S1F 00 ). Most of the enhancer lines also generated cells that dispersed in interneuron-like patterns in the subpallial and pallial amygdala (Figure 2 ; Figures S1A 00 -S1J 00 ).
Enhancer Activity Marks MGE Subregions and Their Pallidal Descendants
Enhancers 1056 and 1538 progenitor (VZ) activities in the E11.5 MGE were largely complementary ( Figures 1D, 1D 00 , 1E, and 1E 00 ). 1538 was active in the rostral and in the dorsal-most MGE, whereas 1056 was active in most of the MGE (mid-rostrocaudal) but was excluded from the dorsal-most 1538 + region (Figures 1D 00 and 1E 00 ). To examine whether these VZ differences altered their pallidal descendants, we compared their fate maps by giving tamoxifen at E10.5 and sacrificing progeny at four ages ( Figure 3 ; Figure S2 ). Analysis at E12.5, E15.5, E17.5, and P40 showed temporal and regional (rostrocaudal) differences in their contribution to the globus pallidus (GP). At E12.5, only 1056 generated clear-cut tdTomato + cells in the GP, whereas by E15.5, both 1056 and 1538 generated GP cells ( Figure S2 ). 1056 was biased to generating caudal parts of the GP, whereas 1538 was biased to generating rostral parts; the rostrocaudal bias was also seen in the E17.5 and P40 fate maps (Figure 3 ; Figure S2 ). These data suggest that the GP may be generated from multiple MGE progenitors, including those enriched rostrodorsally (with 1538 activity) and those enriched ventrally (with 1056 activity).
Enhancers with Different Patterns of MGE Activity Generate Distinct Subsets of Cortical Interneurons Enhancers 1056 and 1538 had distinct patterns of E11.5 MGE activity ( Figures 1D, 1D 00 , 1E, and 1E 00 ), and differentially contributed to rostrocaudal parts of the GP (Figure 3 ; Figure S2 ). Thus, MGE cells with 1056 and 1538 activity may generate distinct distributions of neocortical interneuron subtypes. We fate mapped these enhancer lines to P40 (tamoxifen dose E10.5) ( Figures 4A-4D ). Both enhancers generated parvalbumin (PV + ) and somatostatin (SST + ) interneurons. However, when we compared the PV + /SST + ratios, 1056 generated 2-fold more PV than SST, whereas 1538 generated roughly equal PV and SST numbers ( Figures 4A-4C ). 1056 had E11.5 activity in the dorsal LGE and CGE ( Figure 1) ; accordingly, 12% were REELIN + ;SST À and 7% were VIP + (CGE-type interneurons; Figure 4D ).
Enhancer 1056 mice had neocortical GFP expression at P40, whereas 1538 did not ( Figure S3 ; data not shown). 87% of the GFP expression was in OLIG2 + cells ( Figure S3 ) and thus were in the oligodendrocyte lineage (Silbereis et al., 2014) . <2% of the GFP + ;OLIG2 + double-positive cells were tdTomato + ( Figure S3 ), suggesting that these OLIG2 + cells were generated later than E11.5.
Enhancer 799 P40 mice also had neocortical GFP expression, which was predominantly in SST + interneurons, 5-fold more than in PV + interneurons . 799 had tamoxifen-independent recombination precluding a temporal-specific fate map. 799's temporally integrated fate map showed equal labeling of SST and PV interneurons (Figures 4E 0 , 4F 0 , 4G, and 4H), suggesting that the P40 SST bias was due to preferential 799 activity in SST + neurons at later developmental stages. AAD, anterior amygdaloid area, dorsal; AAV, anterior amygdaloid area, ventral; ac, anterior commissure; Acb, accumbens nucleus; ACo, anterior amygdalar cortical nucleus; al, ansa lenticularis; AOA, anterior olfactory areas; BEC, bed nucleus of the external capsule; BLA, basal lateral amygdala; BLP, basal lateral amygdala posterior; BM, basal medial nucleus of the amygdala; BST, bed nucleus stria terminalis; BSTA, amygdala area of the bed nucleus stria terminalis; BSTsc, subcommissural zone of the bed nucleus stria terminalis; Ce, central amygdala; CeA, central amygdala, anterior part; CeC, central amygdala, central part; CeM, central amygdala, medial part; CGE, caudal ganglionic eminence; CP, choroid plexus; CR, cajal retzius; Cx, cortex; CxA, cortical amygdala transition; DB, diagonal band; DG, dentate gyrus; d, dorsal; GpE, globus pallidus externa; GPI, globus pallidus interna; hem, hem; Hi, hippocampus; hif, hippocampal fissure; Hyp, hypothalumus; IA, interculated amygdala; In, interneurons; Ise, intermediate septum; L, lateral amygdala; LGE, lateral ganglionic eminence; LH, lateral hypothalamus; lot, lateral olfactory tract; MA, medial amygdala region; MeAD, anterodorsal medial amygdala; MePD, posterodorsal medial amygdala; MePV, posteroventral medial amygdala; MGE, medial ganglionic eminence; Mpal, medial pallium; MSe, medial septum; NLOT, nucleus lateral olfactory tract; OB, olfactory bulb; OT, olfactory tubercle; PalSe, pallial septum; PCx, piriform cortex; ped, peduncle; PLCo, posterolateral cortical amygdala nucleus; POA, preoptic area; PTh, prethalmus; PThE, prethalamic eminence; Se, septum; SI, substantia innominata; TCA, thalamocortical axons; Th, thalmus; St, striatum; v, ventral; Vpal, ventral pallidum; VSt, ventral striatum.
Enhancers with CGE MZ Activity Generate SP8 + Amygdala Neurons and Cortical Interneurons Subpallial activity of enhancer 1060 at E11.5 was restricted to the postmitotic mantle zone of the CGE (Figures 1C and C 00 ), with activity (GFP) continuing at E17.5 in the subpallium and in neocortical cells (Data S1C; Figure S4 ). However, no activity (GFP) was detected at P40.
We fate mapped cells in the P40 amygdala using enhancer 1060 activity at several stages (tamoxifen dose at E10.5, E12.5, or E14.5). E10.5 generated cells were deeper (closer to the ventricle along the ventriculo-pial axis) than those generated at E12.5 and E14.5 (Figures 5A-5C; Figure S4 ). E10.5 and E12.5 tdTomato + cells were in the AAD, CeA, CeM, MePD, and MePV; E14.5 tdTomato + cells were largely in the MePV and MePD. To better define the identity of the P40 1060 fate-mapped cells, we used co-labeling experiments with the CGE marker SP8 (Waclaw et al., 2010) ; most of the tdTomato + amygdala cells were double positive ( Figure S4 ). Furthermore, over 80% of the E17.5 1060 fate-mapped amygdala cells co-expressed SP8 and over 90% co-expressed GABA while few co-expressed markers of the central amygdala (Dlx5), the medial amygdala (LHX6, NKX2-1, and OTP), or the pallial amygdala (TBR1), showing a marked specificity of this enhancer for these neurons ( Figure S4 ). E14.5 tamoxifen generated tdTomato + neocortical cells, whereas E10.5 and E12.5 did not ( Figures 5A-5C ). P40 neocortical tdTomato + 1060-lineage cells expressed REELIN and SP8 (CGE markers) but did not express PV or SST (MGE markers) (Figures S4D-S4F ; data not shown). 78% were REELIN + , 75%
were SP8 + , and none were VIP + (Figures 5D-5G ; Figure S4 ). The tdTomato + cells co-expressing REELIN and SP8 were largely in layer 1, supporting a neurogliaform interneuron identity (Miyoshi et al., 2010) .
Fate mapping in the amygdala of enhancer 953, another CGE MZ-selective enhancer ( Figures 1B and 1B 00 ), generated cells that were located in similar positions to those in enhancer 1060 lineage and were largely SP8 + (tamoxifen E10.5; analysis E17.5; Figure 2 ; Figures S1B 00 , S1C 00 , and S4). This E10.5 fatemapping experiment produced no tdTomato + cells in the cortex, whereas a tamoxifen dose at E14.5 (analysis at E17.5) generated neocortical tdTomato + cells, of which roughly 30% were SP8 + ( Figure S4 ).
Transcription Mechanisms that Regulate Enhancer
Activity: Lhx6 and Dlx Increase Enhancer 799 Activity We investigated transcriptional mechanisms that drive the distinct activity patterns of the enhancers. We utilized our laboratory's growing database of TF and histone ChIP-seq results performed on the embryonic subpallium and pallium, which includes ARX, MASHI (ASCL1), COUPTFI (NR2F1), DLX1, DLX2, DLX5, GSX2, LHX6, LHX8, NKX2-1 (TITF1), OTX2, PAX6, PBX, and H3K27Ac (Figures S5H-S5T; Tables S5 and S6 ). Descriptions of these datasets are beginning to be published Pattabiraman et al., 2014; Vogt et al., 2014; Hoch et al., 2015; Golonzhka et al., 2015; Sandberg et al., 2016) . We identified TF ChIP-seq peaks on each of the enhancers and found that all but enhancer 1060 had more than one TF binding ChIP-seq peak ( Figure 6A ; Table S6 ). For instance, in the E13.5 ganglionic eminences, 799 was bound by ARX, DLX1, DLX2, DLX5, PBX, LHX6, LHX8, and NKX2-1. One region of 799 had nearly coincident ARX, DLX1, DLX2, DLX5, LHX6, LHX8, and NKX2-1 peaks ( Figure 6B ). To test whether some of these TFs regulate 799 activity in vivo, we crossed the 799 line with mice harboring Dlx1/2 or Lhx6 null alleles to generate E13.5 embryos with 799 and with homozygous null states of either Dlx1/2 or Lhx6. In each case, GFP (Flandin et al., 2011) and with observed LHX8 binding to 799 ( Figure 6A ). Finally, to gain further evidence that LHX6 directly regulated 799, we searched for candidate Lim/Homeobox binding sites. We found two conserved motifs with the sequence TAATTA. We mutated these sites to TTCTAG (799D2) (asterisks in Figure 6B ) and then tested whether they altered 799 activity in primary E13.5 MGE cultures (Flandin et al., 2011) . 799 was placed upstream of luciferase in the pGL4.23 vector. The wild-type 799 vector drove 2.5-fold more luciferase expression than the vector lacking an enhancer (n = 3, p = 0.0175). Mutation of both LHX6 motifs in 799 eliminated its activity (n = 3, p = 0.0062) ( Figure 6F ). Thus, screening for in vivo TF binding of the enhancer and then challenging these results with in vivo genetics and in vitro molecular biological assays identified transcriptional mechanisms that regulate 799 activity.
TF Binding Predicts Enhancer Regional Activity
We used computational methods to identify enhancer properties that are associated with differences in their activities in distinct subpallial regions and layers (along the axis of differentiation). These computational analyses were performed on the candidate enhancers that exhibited E11.5 subpallial activity in a transgenic assay (Vista Enhancer Browser: http://enhancer.lbl.gov/; Visel et al., 2013) . A subset of these enhancers was analyzed at higher resolution using tissue sectioning, from which we identified 89 enhancers with differential subpallial regional activities (Table  S1 ). These were grouped into six exclusive classes: two single-domain classes, (1) MGE (n = 11) and (2) LGE (n = 22); and four classes with activity in two or more domains: (3) MGE+LGE (n = 43); (4) MGE+LGE+pallium (n = 10); (5) LGE+pallium (n = 2); and (6) CGE+LGE (n = 1). Toward uncovering TF binding that characterizes and distinguishes MGE and LGE activity, we generated three mutually exclusive enhancer superclasses that reflect activity in the MGE and LGE: (1) MGE (n = 11), (2) LGE (n = 25), and (3) MGE+LGE (n = 53).
We applied a machine-learning approach (Breiman 2001 ) (see Experimental Procedures) to identify TFs that may contribute to their region-specific activities using two different sets of features: (1) sequence motifs representing putative TF binding sites and (2) TF in vivo occupancy based on ChIP-seq datasets. Our machine-learning classifier exhibited poor predictive power when trained on sequence motifs with areas under the ROC curve (AUC) close to 0.5 (data not shown). Further inspection of the sequences only revealed a few subtle patterns associated with a small fraction of the enhancers in the dataset. These results may partly reflect the limitations of binding site detection algorithms and deficiencies in the motif databases. As an alternative, we utilized our laboratory's database of histone and TF ChIP-seq experiments (ARX, COUPTFI [NR2F1], DLX1, DLX2, DLX5, GSX2, LHX6, LHX8, MASHI [ASCL1], NKX2-1, OTX2, PAX6, PBX, and H3K27Ac) ( Figure 6A ; Table S5 ; see Experimental Procedures). ChIP-seq peaks on the 89 enhancers with subpallial activity were used as a binary estimate of TF occupancy ( Figure 7A ; Table S6 ). One MGE (408), two LGE (151 and 71), and two MGE and LGE (388 and 426) enhancers did not overlap with any ChIP-seq peak and were excluded from further analysis. Trained on these TF in vivo occupancy data, our machine-learning classifier proved highly accurate at predicting enhancer spatial activity.
First, we trained and tested a classifier to distinguish between the MGE, LGE, and MGE+LGE superclasses. The ability of the classifier to accurately predict enhancer activity was assessed by a leave-one-out cross-validation framework (see Experimental Procedures). Despite the overlap between the domains of activity of the enhancers, the classifier was able to separate each superclass from the other two, with areas under the receiver operating characteristic (ROC) curve (AUCs) of 0.72 (MGE), 0.73 (LGE), and 0.74 (MGE+LGE) ( Figure S5 ).
Next, to gain a better insight into the underlying regulatory mechanisms, we restricted the analysis to the two superclasses of enhancers with specific activity in MGE or LGE ( Figure 7A ).
Once more, the classifier was very efficient at recovering training set members, with an AUC of 0.84 ( Figure S5D) . The examination at E13 of the importance of the variables for the classification 
Figure 7. Transcription Factor Binding Signatures Discriminate Subregional and Laminar Activities of Subpallial Enhancers
See also Figure S5 . (A) Matrix showing the ChIP-seq binding profile of MGE and LGE enhancers. x axis, enhancers with either LGE or MGE (subregional) activity (laminar [VZ and SVZ+MZ] activity is also indicated). y axis, TF ChIP-seq analyses. TF binding to an enhancer with MGE or LGE activity; black and red, respectively. Rows and columns were clustered using complete linkage and a correlation-based distance.
(B) Average ranking of the TF ChIP-seq datasets among the five most discriminative for the 33 LGE and MGE classifiers trained within the leave-one-out crossvalidation framework. The ranking is calculated based on the mean decrease in accuracy associated with each ChIP-seq dataset.
(legend continued on next page) revealed relative enrichment of MGE enhancers as compared to LGE enhancers in binding of LHX6 (8/10 versus 3/23), LHX8 (3/10 versus 0/23), DLX5 (9/10 versus 11/23), and NKX2-1 (9/10 versus 11/23) as the most prominent binding signatures distinguishing MGE and LGE enhancers ( Figures 7B and 7C) . Interestingly, many correctly predicted enhancers (either as MGE or as LGE) exhibit diverse ChIP-seq binding profiles ( Figure 7A ). This diversity of TF binding argues against a rigid combinatorial code and may reflect an even finer grain segmentation of the activities represented by the superclasses, (partial) redundancy between TFs, and/or different contributions of different TFs to enhancer activity.
TF Binding Predicts Enhancer Activity along the Axis of Differentiation
Enhancers also showed subregional activity along the axis of differentiation in the VZ, SVZ, and MZ. The 89 subpallial enhancers were grouped into seven exclusive classes, including three single-layer classes: (1) VZ (n = 26); (2) SVZ (n = 4); (3) MZ (n = 21); (4) SVZ+MZ (n = 31); (5) SVZ+MZ+VZ (n = 4); (6) VZ+SVZ (n = 1); and (7) VZ+MZ (n = 1). As performed for the subpallial regions, we trained a machine-learning classifier based either on sequence motifs representing putative TF binding sites or on TF ChIP-seq data to uncover TF binding that distinguished VZ, SVZ, and MZ activity (see Experimental Procedures). Enhancer classes with less than ten members were disregarded. Four MZ enhancers (151, 71, 388, and 426) and one SVZ+MZ enhancer (408) were excluded from this analysis because of their lack of overlap with ChIP-seq peaks. The classifier that relied on sequence motifs was not successful. In contrast, the classifier trained on ChIP-seq data was highly accurate at separating between VZ, MZ, and SVZ+MZ enhancers, with AUCs of 0.85, 0.73, and 0.77 respectively ( Figures  S5E-S5G) . VZ, MZ, and SVZ+MZ enhancers can be divided according to their ChIP-seq binding profiles into two large groups ( Figure 7D ), one enriched in VZ enhancers (on the left) and one enriched in SVZ+MZ enhancers (on the right). Nevertheless, within these two groups, and as observed for subpallial domains, the enhancers feature variable binding profiles. Examination of the importance of the variables used for the classification revealed differences among VZ, MZ, and SVZ+MZ enhancers in binding of ARX (5/26, 6/17, and 25/30), OTX2 (25/26, 6/17, and 13/30), LHX6 (4/26, 4/17, and 18/30), and PAX6 (23/26, 7/17, and 17/ 30) as the most prominent binding signatures distinguishing the VZ, MZ, and SVZ+MZ enhancers ( Figures 7E and 7F ).
DISCUSSION
We generated stable transgenic mouse lines that expressed CreER T2 and GFP driven by ten different enhancer elements with activity in distinct domains within the E11.5 subpallium (Figure 1) . These enhancer-CreER T2 -GFP lines are useful resources for experimental manipulation of gene expression in specific domains and at specific times. Herein, we used these unique tools to generate two data resources: (1) a regional and cellular fate map of the mouse subpallium that builds on previous studies (Figures 1, 2, 3 , 4, and 5) and (2) . For instance, enhancer 692 MGE activity ( Figures 1G and 1G 00 ; Data S1G) was effective at driving expression in ES cells differentiated into MGE-like neurons. Furthermore, enhancer 1056's persistent activity in maturing/ mature oligodendrocytes ( Figure S3 ) was effective at driving expression in ES cells that differentiate into oligodendrocytes.
Dlx1&2 intergenic enhancers (Ghanem et al., 2007) have broad utility. They function faithfully in ectopic loci , in ES differentiation of MGE-like neurons , in viral vectors used to drive expression in the MGE lineage , and in adult cortical interneurons (Lee et al., 2014) . Thus, enhancer 799, described herein, could be used in a viral vector to drive expression in SST + interneurons. The ten enhancer-CreER T2 -GFP transgenic lines are unique and excellent tools for the generation of several types of data. The CreER T2 module enables these enhancer lines to be used for deletion of floxed genomic loci, such as inducing the expression of reporter genes (e.g., TdTomato) for fate mapping. As illustrated herein, they generated spatial and temporal fate maps from the embryonic subpallium to identify derivatives in the basal ganglia, amygdala, cerebral cortex, and olfactory bulb (Figures 2,  3 , 4, and 5; Data S1A-S1J; Figures S1-S4 ). Table S4 annotates structures and cell types identified by fate mapping from each enhancer line. The CreER T2 module also enables these enhancer lines to inactivate and/or activate other floxed loci, including coding regions, optogenetic genes, and cell death genes for a wide range of experiments. Furthermore, both the GFP and the CreER T2 modules can be used individually or together to enable the purification of cells expressing proteins by virtue of (C) Average ChIP-seq profile for MGE and LGE enhancers shown as a heatmap. y axis, ''relative frequency'' corresponds to the fraction of enhancers containing sites for the indicated TFs (right side).
(D) Matrix showing the ChIP-seq binding profile of enhancers with VZ, SVZ+MZ, and MZ activity (LGE and MGE activity also indicated). Rows and columns were clustered using complete linkage and a correlation-based distance.
(E) Average ranking of the TF ChIP-seq datasets among the five most discriminative for the 73 VZ, SVZ+MZ, and MZ classifiers trained within the leave-one-out cross-validation framework. The ranking is calculated based on the mean decrease in accuracy associated with each ChIP-seq dataset.
(F) Average ChIP-seq profile for VZ, SVZ+MZ, and MZ enhancers shown as a heatmap (see C). See also Figure S5 .
endogenous fluorescence and/or the induction of molecules expressed in distinct organelles. This enables the purification of the cells and/or subcellular compartments for the analysis of RNA and protein expression and/or the cell's genetic and epigenetic state. In addition, as will be further discussed below, these enhancer lines provide unique tools for assessing the in vivo transcriptional regulation of enhancer elements. We demonstrated the ability to define the regional and/or laminar embryonic activity of an enhancer based on its TF ChIP-seq profile (Figure 7 ; Figure S5 ) These results can then be tested in vivo by crossing the enhancer lines with TF mutant alleles (Figure 6 ). Thus, these enhancer transgenic lines are incisive tools for elucidating transcriptional and developmental mechanisms of cell fate. Below, we discuss some of the ways we have already used this resource to derive novel insights into subpallial development.
Subpallial Enhancers Have Dynamic Temporal Activity
Previously published transgenic analysis of these subpallial enhancers interrogated only the E11.5 developmental time point. Using stable enhancer lines, we analyzed enhancer activity at different developmental ages and found varying temporal properties (Figures S1A-S1J ; Tables S2, S3 , and S7). For instance, between E11.5 and E17.5, and roughly within the original expression domain, four enhancers showed similar levels of activity (192, 204, 799, and 1060) , five had reduced activity (599, 692 in MGE, 841, 953, and 1538) , two had increased activity (692 in LGE and 1056), and one was expressed in a new domain (1056 in cortical VZ). Consistent with these results, distinct cohorts of enhancers are active at different stages of brain development (Nord et al., 2013) . In addition, some enhancers were active at multiple stages, such as enhancer 799, which remained active throughout development of cortical interneurons, and persisted preferentially in SST + interneurons ( Figure 4 ; Data S1F).
Fate-Mapping Analyses Define the Regional Derivatives from Distinct Subpallial Progenitor Domains
The transient transgenic analysis of enhancer E11.5 activity (Figures 1A-1J ) led us to hypothesize that these domains represent discrete areal subdivisions of the subpallial progenitors (Figure 1A 00 -1J 00 ) (see Flames et al., 2007; Puelles et al., 2013 Puelles et al., , 2015 . The stable transgenic analysis of E11.5 enhancer activity (GFP expression), and CreER T2 fate analyses at E17.5 and P40, enabled us to ascribe regional fates of many of the proposed progenitor domains (Figures 1A 00 -1J 00 and 2). The expression domains delineated in the schemata of Figures 1A 00 -1J 00 represent the topological relationships of the immature subpallial regions and the fate of their derivatives in the mature telencephalon. These results are consistent with, and substantially add to, previous fate mapping of subpallial regions that used transplantation (chick-quail; Cobos et al., 2001; Garcia-Lopez et al., 2009) and Cre recombination methods (e.g., Fogarty et al., 2007; Xu et al., 2008; Potter et al., 2009; Flandin et al., 2010) .
Our fate mapping identified enhancers with differential activity within VZ subdomains of the LGE and MGE. For instance, within the VZ of the LGE, 841 had activity in the dorsal (d) LGE, whereas 692 did not (Figures 1G 0 , 1H 0 , 2G, and 2H). 841 fate mapping generated olfactory bulb interneurons ( Figure 2H ; Figure S2H ). 1056 and 1538 were differentially active in the VZ of the MGE, being mapped either to ventral (v) MGE and diagonal area (1056) or to the dMGE (1538); fate mapping differentially labeled rostrocaudal (external/internal) subdivisions of the GP and cortical interneuron subtypes (Figures 3 and 4A-4D ; Figure S2 ). Several enhancers that had differential subpallial MZ activity fate mapped to specific neuronal subsets. For instance, 204, 599, 953 , and 1060 generated neurons in a variety of subpallial amygdala nuclei ( Figures 1A-1C, 1I , 2B, 2C, 2I, and 5A-5C; Figures S1A 00 , S1B 00 , S1C 00 , and S1I 00 ). 1060 was particularly intriguing because of its selective CGE activity and because it fate mapped selectively to SP8 + neurons ( Figures 1C, 2C , and 5A-5C; Figures S1C 00 and S4). The LGE activity of enhancers 204 and 599 generated patch-like sets of striatal neurons; future work should establish whether these are striosomes (Figures 1A 0 , 1I 0 ; 2A, and 2I; Data S1A and S1I; Figures S1A 0 and S1I 0 ). Enhancers 799 and 1060 generated MGE-and CGE-derived cortical interneurons, respectively .
Insights into the Transcription Networks Driving Subpallial Regional and Laminar Development and Evolution
In the subpallial primordium, some TFs that control subpallial regionalization (e.g., Nkx2-1) are expressed in highly restricted domains with sharp boundaries (Sussel et al., 1999; Flames et al., 2007; Flandin et al., 2010) , whereas other TFs are expressed in gradients (e.g., CoupTF2 [Nr2f2] and Otx2) that cross some of these boundaries (Hoch et al., 2015 ; J. Hu, S.N.S,. and J.L.R.R., unpublished data). We have identified enhancers whose activities have sharp intrasubpallial boundaries (599, 692, 953, 1006, 1056, and 1538) . We suggest that these enhancer activities reflect the spatial integration of transcriptional activities. Furthermore, these and related enhancers could be regulatory elements that have the potential to drive brain evolution, as transposition of these distant-acting regulators could alter regional gene expression. In that regard, our transgenic assays showed the ability of these enhancers to function in a variety of chromosomal locations.
Currently, we do not have direct evidence for the gene(s) that these enhancers regulate. However, based on proximity and similar expression profiles, we have predictions for enhancer/ gene pairs (Data S1A-S1J; Table S3 ). For instance, enhancers 599, 799, 841, 953, 1056 , 1060 , and 1538 , and Nkx2-1, respectively, and have activities that resemble modules of the subpallial expression of these genes (Data S1A-S1J; Allen Brain Atlas). Furthermore, Lhx6 loss of function reduced Neurexophilin1 expression (J. Chen and J.L.R.R., unpublished data) and also reduced 799 activity (Figures 6D and 6E) . Future studies can test for enhancer/gene interactions using chromatin conformation methods (Clowney et al., 2012) , as well as loss-of-function mutagenesis.
Mechanisms that Regulate Enhancer Activity
We used computational, biochemical, and genetic approaches to identify transcriptional mechanisms controlling enhancer activity. Computational methods have provided insights into candidate TFs that may regulate enhancer activities (Shim et al., 2012; Visel et al., 2013) . However, our motif-based machinelearning approach failed to identify statistically significant nucleotide signatures associated with regional differences in enhancer activities. Heterogeneity of the enhancers, and the lack of accurate motif information for the TFs, could impede the efficacy of pure computational methods. There are few formal analyses that have defined the in vivo motifs that TFs bind to in the embryonic subpallium, with OTX2 being the only example that we are aware of (Hoch et al., 2015) . Most TF ChIP-seq analyses are performed on cells grown in culture, in part because of the complexity of the procedure using specific in vivo tissues. Unless in vitro cells closely approximate in vivo cell types, they may not have the same chromatin environment where the TFs function. We suggest that studies defining in vivo TF motifs will improve the computational approaches. To this end, we used ChIP-seq primarily from the embryonic subpallium to test whether the enhancers under study were bound in vivo by 13 TFs ( Figure 6A ; Tables S5 and S6 ). Then, using machine learning based on transcription factor occupancy, we identified which of these TFs had binding properties that predicted the regional and laminar activity of the enhancers.
Regarding regional properties, LHX6, LHX8, DLX5, NKX2-1, MASH1 (ASCL1), and ARX binding (in order of effect strength) were associated with MGE > LGE activity ( Figures 7B and 7C ). For instance, the absence of LHX6 binding was a good predictor of LGE > MGE activity. Loss-of-function and expression analyses for LHX6, LHX8, and NKX2-1 are consistent with their differential MGE versus LGE functions (Flandin et al., 2011; Liodis et al., 2007; Rubenstein and Campbell; Sussel et al., 1999) .
Although ARX, DLX5, and MASH1 (ASCL1) are expressed in and regulate both the LGE and MGE, there is evidence that in the early (E11.5-E13.5) subpallium Arx, Dlx5&6, and Mash1 (Ascl1) mutants preferentially affect MGE development (Casarosa et al., 1999; Colombo et al., 2007; Wang et al., 2010) .
The same machine-learning paradigm identified which of the 13 TFs had binding properties that predicted the differential activity of the enhancers along the VZ-SVZ-MZ axis of differentiation. For instance, ARX, OTX2, PAX6, LHX6, and DLX1, in order of strength of the effect, predicted differential activity in the VZ compared to the SVZ+MZ (Figures 7E and 7F) . Moreover, the presence of OTX2 binding was a good predictor of VZ > SVZ/ MZ activity. Loss-of-function and expression analyses for Arx, Otx2, Pax6, Lhx6, and Dlx1 are consistent with their differential VZ versus SVZ/MZ functions (Colombo et al., 2007; Flandin et al., 2011; Hoch et al., 2015 , Liodis et al., 2007 Walcher et al., 2013; Yun et al., 2002) . For instance, Otx2 regulates multiple aspects of the subpallial VZ, including the promotion of neurogenesis, oligodendrogenesis, regional identity, and fibroblast growth factor (FGF) signaling (Hoch et al., 2015) . In addition, Dlx1&2 have prominent roles in promoting the differentiation of SVZ and neurons (Yun et al., 2002; Long et al., 2009; Cobos et al., 2007) .
A single enhancer element often was bound by multiple TFs in the embryonic basal ganglia (BG; Figure 6A ). For instance, the MGE enhancer 799 was bound by ARX, DLX1, DLX2, DLX5, LHX6, LHX8, and NKX2-1, and the CGE enhancer 953 was bound by DLX1, DLX2, DLX5, and GSX2 ( Figure 6A ). The joint binding by DLX1, DLX2, and DLX5 could represent redundant functions of these TFs (Long et al., 2009) , whereas the joint binding of the DLX proteins with LHX6, LHX8, NKX2-1, or GSX2 may reflect the relatively MGE-and CGE-specific activities of 799 and 953, respectively. PAX6 ChIP-seq from cortical tissue (Cx) showed binding of 5/10 of the subpallial-specific enhancers ( Figure 6A ). Pax6 represses subpallial gene expression in cortical progenitors (Yun et al., 2001 ). Thus, we suspect that PAX6 binding to 599, 692, 799, 1056 , and 1538 may perform a repressive function on these enhancers.
Five of the 89 enhancers did not have ChIP-seq peaks for any of the 13 TFs tested, including one MGE (408), two LGE (71 and 151), and two MGE and LGE (388 and 426) enhancers. While these could be false negatives, or the enhancers may artificially have subpallial activity, we suggest that other TFs bind in vivo to these loci. We estimate that there are over 290 TFs expressed in the E11.5 subpallium based on analysis of gene expression databases (S.N.S. and J.L.R.R., unpublished data). Thus, the transcriptional mechanisms underlying subpallial development have only begun to be elucidated.
EXPERIMENTAL PROCEDURES Chromatin Immunoprecipitation
ChIP was performed using the methods of Hoch et al. (2015) (see Supplemental Experimental Procedures; Table S5 ). Peaks were visually confirmed and filtered using IGV software (Broad Institute) by considering both input and negative control (Robinson et al., 2011; Thorvaldsdó ttir et al., 2013) .
Computational Analysis and Machine Learning Enhancer Datasets
We restricted the analysis to enhancers exhibiting forebrain activity at E11.5 in the subpallium with little or no activity in the pallium. Activity in other tissues was not considered. Enhancers were categorized based on their subregional activity into three mutually exclusive groups: MGE only, LGE only, or MGE+ LGE (n = 11, 25, and 53, respectively) or based on their layer activity into three groups: VZ, SVZ+MZ, and MZ (n = 26, 31, and 21, respectively). Enhancer Representation ChIP-seq: ChIP-seq peaks mapped to the mouse genome (mm9) were used as a qualitative estimate of TF binding if they overlapped with the mouse genomic location of an enhancer. The enhancer sequences were transformed into multidimensional feature vectors, where each feature corresponds to a TF binding site as determined by ChIP-seq. No other information was supplied to the classifier.
Motifs: The enhancer sequences were transformed into multidimensional feature vectors, where each feature is binary and indicates the presence/absence of a motif representing a predicted TF binding site. Motif occurrences were identified using find individual motif occurrences (FIMO) (Grant et al., 2011 ) with default parameters and three different motif databases. We used the JASPAR CORE 2014 vertebrates (Mathelier et al., 2013) , Human and Mouse HT-SELEX motifs (Jolma et al., 2013) , and UniPROBE Mouse (Newburger and Bulyk, 2009 ) motif databases from the MEME Motif Database (http://meme-suite.org/ db/motifs) and HOCOMOCO (version 9) (Kulakovskiy et al., 2013) .
Machine-Learning Classifier
We constructed random forest (Breiman, 2001) classifiers, consisting of 1,000 decision trees, using the implementation in the ''randomForest'' R package (Liaw and Wiener, 2002) . The optimal value for the number of variables randomly selected for consideration at each split was computed for the training set using the function tuneRF in the randomForest R package with default parameters except for the number of decision trees (1,000). Imbalance in the number of enhancers of each class was addressed using random subsampling. The ability to accurately predict enhancer activity was assessed by a leave-one-out cross-validation procedure. Hence, each point on the ROC curve was generated by training a classifier on all but one of the enhancers and testing it on the remaining enhancer (Figure 7 ; Figure S5 ). Feature Rankings For each of the models, we used the random forest (RF) to rank the importance of the binding sites for the classification of the different groups of sequences as described by (Breiman, 2001 ). Within our leave-one-out cross-validation framework, we obtained as many feature rankings as enhancers in the dataset. The rankings of the top five features in each of these rankings are summarized in Figures 7B and 7E . See Supplemental Experimental Procedures for additional details.
Generation of CT2IG Mice
Enhancers were amplified from human genomic DNA and subcloned into Hsp68-CreERT2-IRES-GFP . Stable transgenic mice were generated by pronuclear injection at the UCSF Transgenic Core using the FVB strain. Founders were screened by PCR (Pattabiraman et al., 2014) .
Image Acquisition
Fluorescent images were taken using a CoolSNAP camera EZ Turbo 1394 digital camera (Photometrics) mounted on a Nikon Eclipse 80i microscope (Nikon Instruments) using NIS Elements acquisition software (Nikon). Brightness and contrast were adjusted and images merged using Adobe Photoshop software.
Immunohistochemistry and In Situ Hybridization
Cell nuclei were stained with Hoechst. TdTomato fluorescence was visualized natively. RNA in situ hybridization and immunohistochemistry are described in Supplemental Experimental Procedures.
Luciferase Assays in Primary Cell Culture and Reporter Vectors MGE was dissected from E11.5 CD1 embryos, dissociated, and transfected with empty firefly-luciferase reporter (pGL4.23), 799 enhancer inserted into pGL4.23 (799GL4.23), or 799 enhancer with two conserved homeobox consensus sites mutated (799DpGL4.23) (see Supplemental Experimental Procedures).
Mouse Husbandry and Lines
Mouse colonies were maintained at the University of California, San Francisco, in accordance with National Institutes of Health and UCSF guidelines. E0.5, midday of vaginal plug. Stable enhancer transgenic, Lhx6 PLAP/PLAP (Flandin et al., 2011) , and Dlx1/2 À/À (Long et al., 2009 ) mice were maintained on CD1 background (Jackson Laboratory). Ai14 mice (Madisen et al., 2010) were C57BL/6J. See Supplemental Experimental Proceduresfor genotyping information of enhancer lines.
Quantification and Statistical Analysis
Quantification was performed on images obtained with a 103 objective. Cells were counted using the cell counter plugin in FIJI software. Statistics were performed using Prism 6 software. See Supplemental Experimental Procedures for description of specific experiments.
Tamoxifen Feeding and Fate Mapping
Male mice heterozygote for both the enhancer CT2IG allele and the Ai14 allele were crossed to CD1 females. Tamoxifen (Sigma-Aldrich) dissolved in corn oil at 10 mg/mL was administered by oral gavage to pregnant CD1 females at a single dose of 1-1.5 mg.
Tissue Preparation
Prenatal heads (E11.5, E12.5, and E13.5) or brains (E15.5 and E17.5) were fixed in 4% paraformaldehyde (PFA) for 2 hr at 4 C, sunk in 30% sucrose, embedded in OCT, and cryosectioned at 20 mM directly onto glass slides. P40 adult mice were perfused with PBS followed by 4% PFA in PBS. Brains were incubated in 4% PFA overnight at 4 C, cryoprotected in 30%
sucrose at 4 C, and sectioned by microtome at 40 mM for free floating immunostaining. 
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